{"id":"W3162972900","doi":"10.1161/strokeaha.120.030565","title":"Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy","year":2021,"lang":"en","type":"article","venue":"Stroke","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University; University of Calgary","funders":"National Institutes of Health; LEO Pharma; University of Calgary; Bristol-Myers Squibb; Eli Lilly and Company; CSL Behring; Alexion Pharmaceuticals; Daiichi Sankyo Europe; Sanofi; Servier; Amgen; National Heart, Lung, and Blood Institute; Pfizer; GlaxoSmithKline","keywords":"Medicine; Hemostasis; Rivaroxaban; Anesthesia; Population; Internal medicine; Apixaban; Surgery; Warfarin; Atrial fibrillation","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00202893,0.0006460995,0.001630061,0.000547633,0.0003692299,0.0008477034,0.0005166528,0.0007025931,0.001559603],"category_scores_gemma":[0.002378934,0.0002743095,0.002016912,0.001053091,0.0004304685,0.0003934649,0.0003645857,0.001041683,0.0002420948],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005077225,"about_ca_system_score_gemma":0.0006578838,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001653928,"about_ca_topic_score_gemma":0.003972768,"domain_scores_codex":[0.9986491,0.0007655742,0.0001826219,0.000118852,0.0001602388,0.0001237273],"domain_scores_gemma":[0.9979721,0.0006395428,0.0008562894,0.0001861042,0.00018356,0.0001624289],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3095977,0.006789251,0.4727372,0.01320438,0.04492,0.0008300922,0.0005803688,0.001114561,0.008446576,0.0004375226,0.009376943,0.1319653],"study_design_scores_gemma":[0.07180749,0.06218196,0.8101862,0.001473628,0.03506223,0.001904571,0.0002705454,0.0007507649,0.003303602,0.0003178414,0.01262612,0.0001150982],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9675519,0.0249409,0.0002033571,0.0002535582,0.00006321229,0.0008223131,0.003588407,0.00002373735,0.002552714],"genre_scores_gemma":[0.9786097,0.01209986,0.0004131124,0.0005801346,0.0003721721,0.001191,0.005985867,0.0000112179,0.0007369946],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00202893,"threshold_uncertainty_score":0.01073015,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03134334231914881,"score_gpt":0.2990814005233223,"score_spread":0.2677380582041735,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}